CF
TRVI icon

Corebridge Financial’s Trevi Therapeutics TRVI Stock Holding History

Corebridge Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,503
Closed -$230K – 2589
2025
Q1 		$230K Buy
36,503
+6,412
+21% +$30.6K ﹤0.01% 1990
2024
Q4 		$124K Sell
30,091
-1,311
-4% -$4.2K ﹤0.01% 2447
2024
Q3 		$105K Sell
31,402
-193
-0.6% -$574 ﹤0.01% 2598
2024
Q2 		$94.2K Buy
+31,595
New +$87.8K ﹤0.01% 2631

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Corebridge Financial's TRVI Position: Q2 2025 in Review

Corebridge Financial sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 36,503 shares — an estimated $230K sold.

Corebridge Financial first reported a position in TRVI in Q2 2024 and held it in 4 quarters. The position peaked at $230K in Q1 2025. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • Corebridge Financial reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 36,503 Trevi Therapeutics shares in Q2 2025, an estimated $230K.
  • Corebridge Financial first reported a position in Trevi Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Trevi Therapeutics position peaked at $230K in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.